Search

Your search keyword '"Khursheed Anwer"' showing total 4 results
Start Over Author "Khursheed Anwer" Language english
4 results on '"Khursheed Anwer"'

1. Determining the Relationship Between Motivation Towards Learning and Academic Performance Among Medical Students

Author

Khursheed Anwer, Qasim Saleem, and Qurrat-Ul-Ain Mehfooz

Subjects
Motivation, goal orientation, learning strategies, locus of control, undergraduate medical students., Medicine (General), R5-920, Dentistry, RK1-715
Abstract

Objective: To find out significant parameters to measure student's learning motivation and examine their relationship with academic performance. Methods: A quantitative correlational study was conducted on 225 MBBS students from May 2018 to June 2018 to examine above mentioned relationship. Stratified random sampling technique was used to draw sample out of accessible population. Data were collected after informed consent from stu- dents using a demographic survey and Modified Archer's Health Professions Motivation Survey (MAHPMS). Information regarding student's scores in their professional examinations was obtained from examination department with due permission. Data were analysed using IBM SPSS 21. Pearson co-efficient of co-relation of four scales of MAHPMS and scores of students were calculated. Scatter plots were used to calculate relationship for each scale of MAHPMS i.e. goal orientation, preference for difficult or easy task, learning strategies and locus of control (independent variables) and marks of students (dependent variable). Results: Goal orientation and marks were 91.7% positively correlated, preference for difficult or easy was 45.6% positively correlated with marks, learning strategies and marks were 48.2% and locus of control and marks were 25.7% positively correlated. Conclusion: Results of the study confirmed that there is positive relationship between student's learning motivation as measured by four sub-scales of MAHPMS and academic performance of students as measured by marks.

Published
2018
Full Text
View/download PDF

2. GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-Escalation Study()

Author

Kunle Odunsi, Ronald D. Alvarez, Wiam Bshara, Premal H. Thaker, Nicholas Borys, William H. Bradley, Charles A. Leath, Khursheed Anwer, Lauren Musso, Camille Gunderson Jackson, and Junko Matsuzaki

Subjects
Cancer Research, medicine.medical_specialty, Myeloid, Paclitaxel, Nausea, medicine.medical_treatment, Population, Neutropenia, Carcinoma, Ovarian Epithelial, Gastroenterology, Article, Carboplatin, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, education, Aged, Neoplasm Staging, Ovarian Neoplasms, Chemotherapy, education.field_of_study, business.industry, Middle Aged, medicine.disease, Debulking, Neoadjuvant Therapy, medicine.anatomical_structure, Oncology, chemistry, Vomiting, Female, medicine.symptom, business
Abstract

Purpose: GEN-1 (phIL-12-005/PPC), an IL12 plasmid formulated with polyethyleneglycol-polyethyleneimine cholesterol lipopolymer, has preclinical activity when combined with platinum-taxane intravenous chemotherapy and administered intraperitoneally in epithelial ovarian cancer (EOC) models. OVATION I was a multicenter, nonrandomized, open-label phase IB trial to evaluate the safety, preliminary antitumor activity, and immunologic response to GEN-1 in combination with neoadjuvant chemotherapy (NACT) carboplatin-paclitaxel in patients with advanced EOC. Patients and Methods: A total of 18 patients with newly diagnosed stage IIIC and IV EOC were enrolled. A standard 3+3 dose-escalation design tested four GEN-1 doses (36, 47, 61, 79 mg/m2) to determine the maximum tolerated dose and dose-limiting toxicities (DLTs). GEN-1 was administered in eight weekly intraperitoneal infusions starting at cycle 1 week 2 in combination with three 21-day cycles of NACT carboplatin AUC 6 and weekly paclitaxel 80 mg/m2. Results: The most common treatment-emergent adverse events at least possibly related were nausea, fatigue, abdominal pain/cramping, anorexia, diarrhea, and vomiting. Eight patients experience grade 4 neutropenia attributed to NACT. No DLTs occurred. A total of 14 patients were evaluable for response and 12 (85.7%) had radiological response (two complete response and 10 partial response) prior to debulking; nine were R0 at debulking and one patient had complete pathologic response. IL12 and its downstream cytokine, IFNγ, increased in peritoneal washings but not as much in blood. Increased levels of myeloid dendritic cells and T-effector memory cells in peritoneal fluid, plus elevated CD8+ T cells and reduced immunosuppression within the tumor microenvironment were found. A median time to treatment failure of 18.4 months (95% confidence interval, 9.2–24.5) was observed in the intention-to-treat population. Conclusions: Adding GEN-1 to standard NACT is safe, appears active, and has an impact on the tumor microenvironment.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results